

**Date Submitted:** 2025-09-30 22:38:43

**Confirmation Number:** 1995043

**Template:** Full CV

---

## **Dr. Saurav Verma**

Correspondence language: English

Sex: Male

Date of Birth: 10/25

Designated Group: Visible Minority

Canadian Residency Status: Permanent Resident

Permanent Residency Start Date: 2024/05/01

Country of Citizenship: India

## **Contact Information**

The primary information is denoted by (\*)

### **Address**

Mailing (\*)

A3-912, Division of Medical Oncology

800 Commissioners Road East

London Ontario N6A5W9

Canada

### **Telephone**

Mobile (\*)

1-519-6972621

### **Email**

Work

saaurav.verma@lhsc.on.ca

(\*)

saauravverma4327@gmail.com

### **Website**

Community

[https://www.schulich.uwo.ca/ctcr/people/our\\_members/uz.html](https://www.schulich.uwo.ca/ctcr/people/our_members/uz.html)

## Dr. Saurav Verma

---

### Language Skills

Language	Read	Write	Speak	Understand	Peer Review
English	Yes	Yes	Yes	Yes	Yes
Hindi	Yes	Yes	Yes	Yes	Yes

### Degrees

2022/7 - 2025/6	Certificate, Clinical Research Fellowship, Clinical Research, University of Western Ontario Degree Status: Completed
2018/7 - 2021/7	Doctorate, Doctorate of Medicine (DM), Medical Oncology, All India Institute of Medical Sciences, New Delhi, India Degree Status: Completed Thesis Title: A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
2015/1 - 2017/12	Doctorate, Doctor of Medicine (MD), Internal Medicine, All India Institute of Medical Sciences, New Delhi, India Degree Status: Completed Thesis Title: Survival Analysis of People Living with HIV/AIDS with Adult HIV Progression Model
2008/8 - 2014/1	Bachelor's, Bachelor of Medicine and Bachelor of Surgery (MBBS), Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India Degree Status: Completed

### Credentials

2025/9	Assistant Professor (Clinician-Researcher) and Medical Oncologist, University of Western Ontario
--------	--

### Recognitions

Conquer Cancer 2025 ASCO Annual Meeting Merit Award - 1,000 (United States dollar)  
American Society of Clinical Oncology  
Prize / Award

Top Oral Abstract Presentation 17th Ontario Thoracic Cancer Conference (2024)  
Ontario Thoracic Association  
Prize / Award

The IASLC Academy Recipient 2025  
The International Association for the Study of Lung Cancer (IASLC)  
Prize / Award

The IASLC Education Award (2022) - 1,200 (United States dollar)  
 The International Association for the Study of Lung Cancer (IASLC)  
 Prize / Award

## User Profile

Researcher Status: Researcher

Engaged in Clinical Research?: Yes

Key Theory / Methodology: Investigator Initiated Trials

Research Interests: Lung Cancer Early-Stage Lung Cancer Biomarkers Immunotherapy Translational Science  
 Drug repurposing

Research Specialization Keywords: Lung Cancer, Thoracic oncology, Clinical Trials, ctDNA, Blood-based biomarkers, Immunotherapy

Disciplines Trained In: Oncology, Internal Medicine

Research Disciplines: Oncology

Areas of Research: Lung Cancer, Cancer Diagnosis and Detection, Immunotherapy

Fields of Application: Biomedical Aspects of Human Health

Geographical Regions: North America

Countries: Canada

## Employment

2025/9	Medical Oncologist London Health Sciences Centre Full-time
2025/9	Assistant Professor University of Western Ontario Full-time
2022/7 - 2023/6	Clinical Research Fellow University of Western Ontario Full-time
2022/1 - 2022/6	Senior Resident Medical Oncology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India Full-time
2021/7 - 2021/12	Senior Resident Medical Oncology, All India Institute of Medical Sciences, New Delhi, India Full-time
2018/7 - 2021/7	Senior Resident Medical Oncology, All India Institute of Medical Sciences, New Delhi, India Full-time
2015/1 - 2017/12	Junior Resident Internal Medicine, All India Institute of Medical Sciences, New Delhi, India Full-time
2013/1 - 2014/1	Intern Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India Full-time

## Affiliations

The primary affiliation is denoted by (\*)

(\*) 2025/9 Assistant Professor, University of Western Ontario

## Research Funding History

### Awarded [n=1]

2022/12 - 2025/12 Medical Oncology Research Fund (MORF), Grant  
 Co-investigator Clinical Research Project?: Yes  
 Project Description: Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT)

## Committee Memberships

2025/2 Committee Member, Systemic Therapy Program Team and Oncology Medication Committee, London Regional Cancer Program  
 2024/12 Committee Member, Health Sciences Research Ethics Board, University of Western Ontario  
 2025/1 - 2025/9 Committee Member, Multi-disciplinary Steering Planning Committee - Strategic Plan 2025-2029, London Regional Cancer Program

## Presentations

- (2025). Impact of stereotactic ablative radiotherapy (SABR) on detection of ctDNA in patients with early-stage lung cancer: Interim findings from the prospective SABR-DETECT trial - A Prospective Cohort Study (POSTER). ASCO Annual Meeting, Chicago, United States of America  
 Main Audience: Researcher  
 Invited?: No, Keynote?: No, Competitive?: Yes
- (2025). Interim results of SABR-DETECT trial. Oncology Education and Research Day, London, Canada  
 Main Audience: Researcher  
 Invited?: No, Keynote?: No, Competitive?: Yes
- (2025). ASCO 2025 Lung Update. Journal Club - Division of Medical Oncology, Western University, London, Canada  
 Main Audience: Researcher  
 Invited?: Yes, Keynote?: No, Competitive?: No
- (2024). ASCO 2024 Lung Update. Journal Club - Division of Medical Oncology, Western University, London, Canada  
 Main Audience: Researcher  
 Invited?: Yes, Keynote?: No, Competitive?: No
- (2024). T-Cell Engager Therapy in Solid Tumors – The Evidence and Managing a New Type of Toxicities. Grand Rounds presentation – Department of Oncology, Western University, London, Canada  
 Main Audience: Researcher  
 Invited?: Yes, Keynote?: No, Competitive?: No

6. (2024). Update on role of immunotherapy in neoadjuvant treatment of early-stage non-small cell lung cancer. Global Thoracic Surgery Telehealth Rounds (Western University), London, Canada  
Main Audience: Researcher  
Invited?: Yes, Keynote?: No, Competitive?: No
7. (2024). Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study (POSTER). World Conference on Lung Cancer 2024, San Diego, United States of America  
Main Audience: Researcher  
Invited?: No, Keynote?: No, Competitive?: Yes
8. (2024). Navigating the Intersection of Clinical Practice and Research – My Early Journey in Investigator-Initiated Studies and Critical Appraisals. Grand Rounds presentation – Department of Oncology, Western University, London, Canada  
Main Audience: Researcher  
Invited?: Yes, Keynote?: No, Competitive?: No
9. (2024). Neoadjuvant immuno-chemotherapy for resectable non-small cell lung cancer – local experience at LRCP (POSTER). Oncology Research and Education Day, Western University, London, Canada  
Main Audience: Researcher  
Invited?: No, Keynote?: No, Competitive?: Yes
10. (2024). Neoadjuvant immuno-chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study. 17th Ontario Thoracic Cancer Conference, Niagara on the Lake, Canada  
Main Audience: Researcher  
Invited?: No, Keynote?: No, Competitive?: Yes
11. (2023). HER2 expression in solid cancers – local experience at LRCP (POSTER). Oncology Research and Education Day, Western University, London, Canada  
Main Audience: Researcher  
Invited?: No, Keynote?: No, Competitive?: Yes
12. (2023). Overview of treatment landscape in resectable lung cancer, local experience in with neoadjuvant immunotherapy in resectable NSCLC. Thoracic Disease Site Retreat, London Regional Cancer Program, London, Canada  
Main Audience: Researcher  
Invited?: Yes, Keynote?: No, Competitive?: No
13. (2022). A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer (POSTER). World Conference on Lung Cancer, Vienna, Austria  
Main Audience: Researcher  
Invited?: No, Keynote?: No, Competitive?: Yes
14. (2022). Pre-PLaN study. Thoracic Disease Site Retreat, London Regional Cancer Program, London, Canada  
Main Audience: Researcher  
Invited?: Yes, Keynote?: No, Competitive?: No
15. (2020). Case Presentation on 'Small cell transformation in EGFR mutated NSCLC'. Oncobridge NSCLC meeting, New Delhi, India  
Main Audience: Researcher  
Invited?: Yes, Keynote?: No, Competitive?: No

## Publications

### Journal Articles

1. (2025). The TROP2 paradox: enhancing precision in immunotherapy for advanced non-small cell lung cancer patients—a commentary. AME Translational Cancer Research. DOI: AME Translational Cancer Research.  
<http://dx.doi.org/10.21037/tcr-24-1633>  
Co-Author  
Published, AME Publishing Company,
2. (2025). When to initiate durvalumab after concurrent chemoradiation in unresectable stage III non-small cell lung cancer? - A commentary on the phase II TORG 1937 (DATE) study. Journal of Thoracic Disease.  
<http://dx.doi.org/10.21037/jtd-2024-2100>  
Co-Author  
Published, AME Publishing Company,
3. (2025). Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer-A Narrative Review. Current Oncology.  
<http://dx.doi.org/10.3390/curroncol32080448>  
Co-Author, MDPI,
4. (2024). The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial \. AME Clinical Trials Review.  
<http://dx.doi.org/10.21037/actr-24-41>  
First Listed Author  
Published,
5. (2024). An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers.  
<http://dx.doi.org/10.3390/cancers16071302>  
First Listed Author  
Published, MDPI,
6. (2024). Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort. Single-Institution Prospective Cohort Exploration of Targeted Anti-tumor Therapy.  
<http://dx.doi.org/10.37349/etat.2024.00265>  
First Listed Author  
Published, Open Exploration,
7. (2024). The Current Role of Radiation in the Management of Cholangiocarcinoma – A Narrative Review. Cancers.  
<http://dx.doi.org/DOI: 10.3390/cancers16091776>  
First Listed Author  
Published, MDPI,
8. (2023). Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review. DOI: First Listed Author Published, .International Journal of Radiation Oncology, Biology, Physics.  
<http://dx.doi.org/10.1016/j.ijrobp.2024.01.001>  
First Listed Author  
Published, IJROBP, ASTRO,

9. (2023). Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients with Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis. American Journal of Clinical Oncology.  
<http://dx.doi.org/10.1097/COC.0000000000000976>  
Co-Author  
Published, Wolters Kluwer,
10. (2023). Perioperative Chemo-Immunotherapy in Stage III Non–Small-Cell Lung Cancer - Letter to Editor. The New England Journal of Medicine.  
<http://dx.doi.org/10.1056/nejmc2310641>  
First Listed Editor  
Published, The New England Journal of Medicine,
11. (2023). Survival of persons living with HIV/AIDS: A multicentric study from India. Current HIV research.  
<http://dx.doi.org/10.2174/1570162X21666230123151639>  
Co-Author  
Published, Bentham Science,
12. (2023). ‘Targeting’ Improved Outcomes with Antibody-Drug conjugates in Non-Small Cell Lung Cancer – An Updated Review. Current Oncology.  
<http://dx.doi.org/10.3390/curroncol30040330>  
First Listed Author, MDPI,
13. (2023). Detection of Circulating Tumor DNA after Stereotactic Ablative Radiotherapy in Patients with Unbiopsied Lung Tumors (SABR-DETECT) – Trial Protocol. Clinical Lung Cancer.  
<http://dx.doi.org/10.1016/j.clcc.2023.11.013>  
First Listed Author  
Published, Elsevier,
14. (2023). The Role of Thoracic Consolidative Radiotherapy in the Setting of Immunotherapy in Extensive Stage Small Cell Lung Cancer. Therapeutic Advances in Medical Oncology (TAM).  
First Listed Author  
Submitted,
15. (2023). Impact of Oncology Drug Review Times on Public Funding Recommendations. Current Oncology.  
<http://dx.doi.org/10.3390/curroncol30080558>  
Published, MDPI,
16. (2023). A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer. Medical Oncology.  
<http://dx.doi.org/10.1007/s12032-023-02057-y>  
First Listed Author, MDPI,
17. (2022). Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer - An exploratory analysis. Cancer Treatment and Research Communications.  
<http://dx.doi.org/https://doi.org/10.1016/j.ctarc.2022.100520>  
First Listed Author  
Published, Elsevier,
18. (2022). Autologous Hematopoietic Stem Cell Transplant: A Potential Option for Relapsed Pediatric Acute Myeloid Leukemia With Lack of Matched Sibling Donor and Resource Challenge. Journal of Pediatric Hematology/Oncology.  
<http://dx.doi.org/10.1097/MPH.0000000000002222>  
Co-Author  
Published, Wolters Kluwer,

19. (2021). Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India. Future Science OA.Future Science OA.  
<http://dx.doi.org/https://doi.org/10.2144/fsoa-2020-0178>  
 First Listed Author  
 Published, Future Science,
20. (2021). Trabectedin in Advanced Sarcomas-Experience at a Tertiary Care Center and Review of Literature.South Asian Journal of Cancer.  
<http://dx.doi.org/10.1055/s-0041-1734336>  
 First Listed Author  
 Published, Thieme,
21. (2021). Neoadjuvant Systemic Chemotherapy in Sebaceous Gland Carcinoma of the Eyelid: A Retrospective Study.Ocular Oncology and Pathology.  
<http://dx.doi.org/10.1159/000515857>  
 First Listed Author  
 Published, Karger,
22. (2020). Utility and safety of maintenance chemotherapy in advanced non–small cell lung cancer across various performance status categories: real- world experience.Current Problems in Cancer.  
<http://dx.doi.org/10.1016/j.currproblcancer.2020.100565>  
 Co-Author  
 Published, Elsevier,
23. (2020). Clinical approach to childhood mediastinal tumors and management.Mediastinum.  
<http://dx.doi.org/10.21037/med-19-82>  
 First Listed Author  
 Published, AME publishing company,
24. (2020). A case report of Kaposiform haemangioendothelioma; response with propranolol and steroids. Clinical Sarcoma Research.  
<http://dx.doi.org/10.1186/s13569-020-00134-8>  
 First Listed Author  
 Published, BMC,
25. (2020). Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma. Clinical Sarcoma Research. Clinical Sarcoma Research.  
<http://dx.doi.org/10.1186/s13569-020-00149-1>  
 First Listed Author  
 Published, BMC,
26. (2019). Outcomes in rhabdomyosarcoma: Indian perspective.Cancer Research, Statistics, and Treatment.  
[http://dx.doi.org/10.4103/CRST.CRST\\_74\\_19](http://dx.doi.org/10.4103/CRST.CRST_74_19)  
 First Listed Author  
 Published, Wolters Kluwer,

## Book Chapters

1. (2021). Lung Cancer. Postgraduate Medicine. 1/e(3): 1747-1757.  
 Co-Author  
 Published, Jaypee publishers,

## Thesis/Dissertation

1. A phase II study of Metformin plus Pemetrexed/Carboplatin in Patients with Advanced/Metastatic Non-Squamous Non-Small Cell Lung cancer. (2021). All India Institute of Medical Sciences. Doctorate.



2. Survival Analysis of People Living with HIV/AIDS with Adult HIV Progression Model. (2017). All India Institute of Medical Sciences. Doctorate.

## Supervised Student Publications

1. Matthew Anthony Neil Van Oirschot  
Raltitrexed as a substitute for 5-fluorouracil in combination with pembrolizumab and platinum in a patient with metastatic esophageal squamous cell carcinoma and coronary artery disease: a case report. *Annals of Translational Medicine*. (2025).  
<http://dx.doi.org/10.21037/atm-25-38>  
Published,
2. Tia Brasoveanu  
Circulating tumor DNA as part of the routine work-up for patients with suspected advanced lung cancer. *Journal of Liquid Biopsy*. (2024).  
<http://dx.doi.org/10.1016/j.jlb.2024.100194> External Link  
Published,

## Conference Publications

1. (2025). Impact of stereotactic ablative radiotherapy (SABR) on detection of ctDNA in patients with early-stage lung cancer: Interim findings from the prospective SABR-DETECT trial. *Journal of Clinical Oncology*. ASCO Annual Meeting, Chicago, United States of America,  
[http://dx.doi.org/10.1200/JCO.2025.43.16\\_suppl.3044](http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.3044)  
Conference Date: 2025/6  
Abstract  
First Listed Author  
Published
2. (2025). Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study. *Journal of Thoracic Oncology*. WCLC Annual Meeting, San Diego, United States of America,  
<http://dx.doi.org/10.1016/j.jtho.2024.09.445>  
Conference Date: 2024/9  
Abstract  
First Listed Author  
Published
3. (2024). Analysis of Variables Predicting pCR and irAEs in Resectable NSCLC Receiving Neoadjuvant Immunotherapy with Chemotherapy (Pre-PLaN). *Journal of Thoracic Oncology*. WCLC Annual Meeting, San Diego, United States of America,  
<http://dx.doi.org/10.1016/j.jtho.2024.09.1046>  
Conference Date: 2024/9  
Abstract  
First Listed Author  
Published
4. (2024). Neoadjuvant immuno-chemotherapy in resectable non-small cell lung cancer: A retrospective cohort study. *Journal of Clinical Oncology*. ASCO Annual Meeting, Chicago, United States of America,  
[http://dx.doi.org/10.1200/JCO.2024.42.16\\_suppl.e20077](http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.e20077)  
Conference Date: 2024/6  
Abstract  
First Listed Author  
Published

5. (2023). First line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis). Annals of Oncology. ESMO Annual Meeting, Madrid, Spain, <http://dx.doi.org/10.1016/j.annonc.2023.09.2360>  
Conference Date: 2023/10  
Abstract  
Co-Author  
Published
6. (2022). A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. World Conference on Lung Cancer, Vienna, Austria,  
Conference Date: 2022/8  
Abstract  
Published
7. (2021). Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer. Journal of Clinical Oncology. ASCO Genitourinary Cancers Symposium, San Francisco, United States of America,  
Conference Date: 2021/2  
Abstract  
Published
8. (2019). Thymidylate Synthase and Folate Receptor Alpha Expression as Potential Biomarkers for Efficacy of Pemetrexed in NSCLC. Journal of Thoracic Oncology. World Conference on Lung Cancer, Barcelona, Spain,  
Conference Date: 2019/9  
Abstract  
Published

**Date Submitted:** 2025-09-30 13:23:01

**Confirmation Number:** 1994763

**Template:** Full CV

---

## **Dr. Mark Vincent**

Correspondence language: English

Sex: Male

Date of Birth: 9/01

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

## **Contact Information**

The primary information is denoted by (\*)

### **Address**

#### Courier

800 Commissioners Rd. E.  
PO Box 5010, Stn B  
London Ontario N6A 5W9  
Canada

#### Primary Affiliation (\*)

800 Commissioners Rd. E.  
PO Box 5010, Stn B  
London Ontario N6A 5W9  
Canada

### **Telephone**

Fax	1-519-6858624
Work (*)	1-519-6858634
Work	1-519-6858640

### **Email**

Work (*)	mark.vincent@lhsc.on.ca
----------	-------------------------

### **Website**

Corporate	www.myoncologyresource.com
-----------	----------------------------

## Dr. Mark Vincent

---

### Language Skills

Language	Read	Write	Speak	Understand	Peer Review
Afrikaans	Yes	Yes	Yes	Yes	
English	Yes	Yes	Yes	Yes	

### Degrees

1971/7 - 1976/7 Bachelor's, MB ChB, South Africa  
 Degree Status: Completed  
 Research Disciplines: Oncology

### Credentials

1992/7 Certificate Special Competence, Medical Oncology, Royal College of Physicians and Surgeons of Canada  
 1991/7 FRCPC, Royal College of Physicians and Surgeons of Canada  
 1991/1 General Medical Licence, College of Physicians and Surgeons of Ontario  
 1991/1 LMCC, Medical Council of Canada  
 1980/1 MRCP(UK), Royal College of Physicians (UK)

### Recognitions

2007/1 - 2008/1 Award of Excellence in Teaching (Canadian dollar)  
 the University of Western Ontario  
 Distinction  
 2004/5 - 2005/5 Award of Excellence in Teaching  
 the University of Western Ontario  
 Distinction  
 1976/6 Gold Medals in Chemistry and Physiology  
 University of Capetown, South Africa  
 Distinction  
 Chemistry and Physiology  
 1976/5 Honours 1st, 2nd, final professional exam  
 University of Capetown, South Africa  
 Distinction

### User Profile

Engaged in Clinical Research?: Yes

Research Interests: Reversal of drug resistance Prediction of chemotherapy toxicity

Research Specialization Keywords: antisense, cancer, clinical trials, colorectal, DNA damage repair, esophageal, gastrointestinal, immune checkpoint inhibitors, lung, mesothelioma, small molecule therapeutic, tesmilifene, thymidylate synthase

Disciplines Trained In: Oncology

Research Disciplines: Oncology

Areas of Research: Cancer Diagnosis and Detection, Cancer of the Digestive System, Chemotherapy, Health Policies, Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

## Employment

2018/1	Thoracic Disease Site Team Chair Oncology, Oncology / Western University, London Regional Cancer Program Full-time, Term
2012/7	Professor of Oncology (Senate Stream) Division of Medical Oncology, University of Western Ontario, University of Western Ontario Full-time, Professor
1998/7	Associate Professor Division of Medical Oncology, Oncology / Western University, University of Western Ontario Full-time, Associate Professor
1998/1	CEO and Co-Founder and President, Sarissa Inc. Sarissa Inc. Full-time
1991/7	Assistant Professor Division of Medical Oncology, Oncology / Western University, University of Western Ontario Full-time, Assistant Professor Research Disciplines: Oncology

## Affiliations

The primary affiliation is denoted by (\*)

(\*) 2012/7 Full Professor, University of Western Ontario

## Research Funding History

### Awarded [n=5]

2023/6 - 2025/5 Analysis of variables predicting complete pathological response in patients with resectable  
Principal Investigator NSCLC receiving neoadjuvant immunotherapy with chemotherapy- a prospective cohort study

**Funding Sources:**

London Health Sciences Centre  
 Medical Oncology Research Fund (MORF)  
 Total Funding - 29,834  
 Funding Competitive?: Yes

2020/1 - 2024/12  
 Principal Investigator Osimertinib rechallenge after chemotherapy in EGFR-mutated lung cancer Third Line (OCELOT, a phase II clinical trial)

**Funding Sources:**

2020/1 - 2024/12 AstraZeneca Canada Inc.  
 Externally Sponsored Research (ESR)  
 Total Funding - 4,000,000 (Canadian dollar)  
 Funding Competitive?: Yes

1993/4 - 2019/12  
 Co-investigator Antisense-mediated modification of cellular drug resistance: Thymidylate synthase., Grant

**Funding Sources:**

1993/4 - 2019/12 AstraZeneca Canada Inc.  
 AstraZeneca Canada Inc.  
 Total Funding - 404,055 (Canadian dollar)  
 Funding Competitive?: Yes

2017/6 - 2019/5  
 Principal Applicant Small molecule modulation of drug resistance to EGFR tyrosine kinases, Grant  
 Clinical Research Project?: Yes  
 Project Description: \$500,000 London Health Sciences Centre

**Funding Sources:**

2017/6 - 2019/5 London Health Sciences Foundation  
 London Health Sciences Foundation  
 Total Funding - 500,000 (Canadian dollar)  
 Funding Competitive?: No

2017/5 - 2018/4  
 Principal Applicant Modulation of drug resistance to targeted agents, Grant  
 Clinical Research Project?: Yes  
 Project Description: MORF (Medical Oncology Research Fund) \$30,000 London Health Sciences Centre

**Funding Sources:**

2017/5 - 2018/4 Division of Medical Oncology  
 Medical Oncology Research Fund  
 Total Funding - 30,000 (Canadian dollar)  
 Funding Competitive?: Yes

**Completed [n=1]**

2015/8 - 2016/8  
 Principal Investigator Modulation of drug resistance to targeted agents, Grant  
 Clinical Research Project?: Yes  
 Project Description: Medical Oncology Research Fund (MORF) \$30,000 London Health Sciences Centre

**Funding Sources:**

2015/8 - 2016/8 Division of Medical Oncology  
 Medical Oncology Research Fund  
 Total Funding - 30,000 (Canadian dollar)  
 Funding Competitive?: Yes

## Student/Postdoctoral Supervision

### Doctorate [n=1]

2010/1 - 2015/6  
Co-Supervisor Mateusz Rytelewski (Completed) , Western University  
Student Degree Start Date: 2010/9  
Student Degree Received Date: 2015/6  
Thesis/Project Title: Overcoming Innate and Acquired Therapy Resistance by Targeting DNA Repair in Human Cancer Cells  
Present Position: Post-doctoral Fellow

### Post-doctorate [n=11]

2022/7  
Principal Supervisor Saurev Verma (In Progress) , The University of Western Ontario  
Student Degree Start Date: 2022/7  
Student Degree Expected Date: 2024/6  
Thesis/Project Title: Lung Fellowship in Medical Oncology  
Present Position: Post-doctoral fellow

2021/7  
Principal Supervisor Scott Strum (In Progress) , The University of Western Ontario  
Student Degree Start Date: 2022/7  
Student Degree Expected Date: 2023/6  
Thesis/Project Title: Medical Oncology Residency  
Present Position: Resident

2019/7 - 2020/5  
Principal Supervisor Daniel Breadner (Completed) , The University of Western Ontario  
Student Degree Start Date: 2019/7  
Student Degree Received Date: 2020/6  
Thesis/Project Title: Personalized Medicine Fellowship  
Present Position: Medical Oncologist

2010/1  
Principal Supervisor Fulan Cui (Completed) , The University of Western Ontario  
Student Degree Start Date: 2017/6  
Student Degree Received Date: 2018/7  
Thesis/Project Title: Cancer  
Present Position: Resident

2010/1  
Principal Supervisor Isabelle Li (Completed) , The University of Western Ontario  
Student Degree Start Date: 2010/6  
Student Degree Received Date: 2011/5  
Thesis/Project Title: Cancer  
Project Description: Incidence of Wound Complications in Neoadjuvant versus Adjuvant Treatment of Locally Advanced Resectable Rectal Cancers  
Present Position: Medical Oncologist

2010/1  
Principal Supervisor Michael Ong (Completed) , King's College  
Student Degree Start Date: 2010/6  
Student Degree Received Date: 2011/5  
Thesis/Project Title: Cancer  
Project Description: Current systemic therapies for advanced non-small cell lung cancer  
Present Position: Research Fellow

2010/1 Principal Supervisor	Peter luk (Completed) , University of New South Wales Student Degree Start Date: 2008/9 Student Degree Received Date: 2010/6 Thesis/Project Title: The Influence of the EGFR Pathway in Modulating the Efficacy of Gemcitabine. Present Position: Medical Oncologist
2010/1 Co-Supervisor	Kathleen Calonego (Completed) , University of Toronto Student Degree Start Date: 2007/9 Student Degree Received Date: 2009/9 Thesis/Project Title: Cancer Project Description: Antisense targeting of TS and IDO for anticancer therapy Present Position: Family physician
2010/1 Principal Supervisor	Sanatani Michael (Completed) , The University of Western Ontario Student Degree Start Date: 2007/1 Student Degree Received Date: 2007/12 Thesis/Project Title: Quality Of Life Project Description: Risk and benefit for first-line treatment of metastatic colorectal cancer Present Position: Medical Oncologist
2010/1 Principal Supervisor	Cheryl Ho (Completed) , University of British Columbia, BC Cancer Agency Student Degree Start Date: 2002/1 Student Degree Received Date: 2002/12 Thesis/Project Title: Cancer Project Description: Toxicity of the 5-day bolus 5-fluorouracil/folinic acid regimen for treatment of colorectal carcinoma Present Position: Medical Oncologist
2010/1 Principal Supervisor	Anna Tomiak (Completed) , Queen's University Student Degree Start Date: 2001/1 Student Degree Received Date: 2001/12 Thesis/Project Title: Cancer Project Description: Thymidylate synthase expression in stage II and III colon cancer Present Position: Medical Oncologist

## Staff Supervision

## Mentoring Activities

2017/10 - 2021/12	Mentor, London Regional Cancer Program Number of Mentorees: 1 Mentorees: Jacques Rapheal Currently mentoring Dr. Jacques Raphael
-------------------	---

## Journal Review Activities

Manuscript Reviewer, Journal of Thoracic Oncology  
Manuscript Reviewer, Bioessays



## Knowledge and Technology Translation

2007/1	Independent Director, Consultation Service Target Stakeholder: Patients Activity Description: <b>Aptose Biosciences Inc.</b> Chair, Corporate Governance and Nominations Committee
2001/1	Founder/CEO, Involvement in/Creation of Start-up Target Stakeholder: Patients Activity Description: <b>Sarissa Inc.</b> Founder/CEO involved in ongoing development of RAD51 small molecule inhibitor(s); development of agents to potentiate immune checkpoint inhibitors and PARP inhibitors
1992/1	Committee Member, Policy/Regulation Development Target Stakeholder: Policy Maker/Regulator Activity Description: <b>Ontario Ministry of Health</b> Guideline Committee Member for thoracic malignancies
2021/5 - 2022/5	Consultant, Consulting for Industry Target Stakeholder: General Public Activity Description: <b>Drug Royalty Corporation (now DRI)</b> Consultant and Advisor on potential for new drug approval in the United States and Europe in Oncology

## Committee Memberships

	Chair, YM Biosciences
	Committee Member, Technical Advisory Board - Critical Outcomes Technology Inc.
	Committee Member, Small Grants Committee, London Regional Cancer Program
	Committee Member, Integrated Care Task Group, London Regional Cancer Program
	Committee Member, Tumor Board Access Committee, London Regional Cancer Program
	Committee Member, Tumor Board Operations Committee, London Regional Cancer Program
2012/1	Committee Member, Merck Inc. Advisory Board
2012/1	Committee Member, Boehringer Ingelheim Inc. Speakers Panel International: Middle East
2009/1	Committee Member, Eli Lilly Inc. Speakers Panel, Eli Lilly and Company International: >25 Countries
2008/1	Chair, Aptose Biosciences Inc. Corporate Governance and Nominating Committee
2008/1	Committee Member, Critical Outcomes Tehcnology Inc. Technical Advisory Board
2007/1	Committee Member, Lorus Therapeutics (Now Aptose Biosciences Inc.)
1999/1	Committee Member, Roche Pharmaceuticals Advisory Board
1991/1	Committee Member, Astra Zeneca Canada Advisory Board
1991/1	Committee Member, Amgen Inc. Advisory board and speaker panel (Canada)
1991/1	Committee Member, Bristol Myers Squibb Inc. Advisory Board
2007/1 - 2008/1	Committee Member, Lorus Therapeutics (now Aptose Biosciences Inc.) Environmental Health and Safety Committee
2005/1 - 2007/1	Committee Member, Capital Royalty Scientific Advisory Board

1995/1 - 2005/1	Committee Member, Systemic Treatment Program Committee (STPT), London Regional Cancer Program
1993/1 - 2005/1	Committee Member, Medical Oncology Protocol Review Committee, London Regional Cancer Program

## Other Memberships

2009/1	Member, European Society of Medical Oncology
1991/1	Member, Ontario Medical Association (OMA)
1991/1	Member, Canadian Medical Association (CMA)
1989/1	Member, International Association for the Study of Lung Cancer
1989/1	Member, Royal College of Physicians and Surgeons of Canada
1989/1	Member, Canadian Association of Medical Oncologists
1989/1	Member, College of Physicians and Surgeons of Ontario
1989/1	Member, New York Academy of Sciences
1989/1	Member, American Society of Clinical Oncology (ASCO)
1980/1	Member, Royal College of Physicians
1993/1 - 2000/1	Member, National Cancer Institute Phase I Working Group

## Presentations

- (2022). Atavism, Extinction Theory and the Treatment of Cancer. Atavistic Theory of Cancer Workshop, France  
Main Audience: Researcher  
Invited?: Yes, Keynote?: Yes
- (2020). Updates of World Conference on Lung Cancer. Eli Lilly, Mexico  
Main Audience: Knowledge User
- (2020). Novartis National Virtual Lung Cancer Consult Meeting, Canada  
Main Audience: Knowledge User
- (2020). Understanding the Treatment Strategies in LA NSCLC & the Role of the Immune System in NSCLC. AstraZeneca, Egypt  
Main Audience: Knowledge User
- (2020). Challenges and Treatment Approaches in Management of ES-SCLC. Evaluating New Opportunities To improve Outcomes (AstraZeneca), United Arab Emirates  
Main Audience: Knowledge User
- (2020). Immunotherapy in Stage 111 NSCLC: Unleashing the immunogenic potential of cCRT. AstraZeneca, Saudi Arabia  
Main Audience: Knowledge User
- (2019). Cancer from the Evolutionary Perspective. ICRC Symposium (Invited by Dr. John McDonald), United States of America  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: Yes

8. (2019). Management of stage III NSCLC. AstraZeneca, India  
Main Audience: Knowledge User
9. (2019). IMFINZI Launch. AstraZeneca, Egypt  
Main Audience: Knowledge User
10. David Planchard (Gustave Roussy, Paris, France). (2018). Practice Change in Canada. Lung Cancer National Symposium, Japan  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: Yes
11. (2018). Why atavism must now be taken seriously as an explanation for cancer. Centre International de Rencontres Mathématiques, France  
Main Audience: Knowledge User  
Invited?: Yes
12. (2018). Drug Resistance in Cancer as an Atavism. CMM- Fields-INRIA Workshop on Mathematics, Canada  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: Yes
13. (2018). Lung Cancer Management – update: Personalized approach in 2nd line Management. NSCLC, Boehringer-Ingelheim, Kuwait  
Main Audience: Knowledge User  
Invited?: Yes
14. (2018). Management update in NSCLC: Afatinib in 1st line NSCLC, EGFR M+Customized Approach in management of 2L -NSCLC. Boehringer-Ingelheim, United Arab Emirates  
Main Audience: Knowledge User  
Invited?: Yes
15. (2018). Perspective on the Evolution of Molecular Therapy in Cancer. Eli Lilly, Mexico  
Main Audience: Knowledge User
16. (2018). Cancer as a re-primitivized phenotype. Arizona State University - NIH sponsored, United States of America  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: No
17. (2017). Comprehensive Strategic Approach to NSCLC. Eli Lilly, Mexico  
Main Audience: Knowledge User  
Invited?: Yes
18. Ferguson PJ, Rytelowski M, Vincent M, Koropatnick J. (2016). Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of RAD51: targeting DNA repair to induce synthetic lethality. American Association of Cancer Research (AACR), New Orleans, United States of America  
Main Audience: Knowledge User  
Invited?: Yes, Keynote?: No

## Publications

### Journal Articles

1. Melosky B, Chu QSC, Juergens RA, Snow S, Blais N, Cheema P, Sangha R, Agulnik J, Martins I, Burkes RL, Poonja Z, Vincent MD, Liu G. (2025). Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC. Lung Cancer. 208: 108717.  
<http://dx.doi.org/doi: 10.1016/j.lungcan.2025.108717>  
Published,

2. Melosky B, Vincent MD, McGuire AL, Brade AM, Chu Q, Cheema P, Martins I, Spicer JD, Snow S, Juergens RA. (2024). Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer. *International Journal of Cancer*. 155(6): 963-978.  
<http://dx.doi.org/DOI: 10.1002/ijc.35031>  
Published,
3. Cheung WY, Samimi S, Ma K, Knight GJ, Kassam S, Colwell B, Beaudoin A, Vincent MD, Trinkaus M, Fillion A, Marquis K, Karachiwala H, Asmis T, Sideris L, Wani RJ, Ngan E, Inam N, Du Y, Nunez L, Eberg M, Alemayehu M, Meyer PF, Mancini J, Cirone Morris C. (2024). Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada. *Clinical Colorectal Cancer*. 23(1): 46-57.  
<http://dx.doi.org/DOI: 10.1016/j.clcc.2023.10.007>  
Published,
4. Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. (2023). Sotorasib in *KRAS* p.G12C-Mutated Advanced Pancreatic Cancer. *The New England Journal of Medicine*. 388(1): 33-43.  
Published,
5. Preti BTB, Sanatani MS, Breadner D, Lakkunarajah S, Scott C, Esmonde-White C, McArthur E, Rodrigues G, Chaudhary M, Mutsaers A, Sachdeva R, Vincent MD. (2023). Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer. *Current Oncology*. 30(8): 7713-7721.  
<http://dx.doi.org/DOI: 10.3390/curroncol30080559>  
Published,
6. Preti B, Schenkel L, Cecchini M, Romagnoli T, Sanatani MS, French K, Colquhoun P, Vincent MD. (2023). Double Duty: Complete Pathologic Response of Two Colonic Primaries with Mosaicism of a Novel *MLH1* Mutation to Neoadjuvant Pembrolizumab. *Current Oncology*. 30(10): 9039-9048.  
<http://dx.doi.org/DOI: 10.3390/curroncol30100653>  
Published,
7. Scott Strum, Michael Mitchell, Hooman Ganjavi, Mark Vincent. (2023). Oxidative-stress induced pulmonary toxicity in a 46-year-old male with G6PD deficiency on chemotherapy. *Current Problems in Cancer: Case Reports*. 9(100215): 1-3.  
Published,
8. Breadner DA, Vincent MD, Correa R, Black M, Warner A, Sanatani M, Bhat V, Morris C, Jones G, Allan A, Palma DA, Raphael J. (2022). Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study. *Lung Cancer*. 165: 145-151.  
Published,
9. Yaremko BP, Capaldi DPI, Sheikh K, Palma DA, Warner A, Dar AR, Yu E, Rodrigues GB, Louie AV, Landis M, Sanatani M, Vincent MD, Younus J, Kuruvilla S, Chen JZ, Erickson A, Gaede S, Parraga G, Hoover DA. (2022). Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): Results of a Double-Blind, Randomized Controlled Trial. *International Journal of Radiation Oncology, Biology, Physics*. S0360-3016(22): 00408-4.  
Published,
10. Yu E, Allan AL, Sanatani M, Lewis D, Warner A, Dar AR, Yaremko BP, Lowes LE, Palma DA, Raphael J, Vincent MD, Rodrigues GB, Fortin D, Inculet RI, Frechette E, Bierer J, Law J, Younus J, Malthaner RA. (2022). Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial. *BMC Cancer*. 22(1): 746.  
Published,

11. Malthaner RA, Yu E, Sanatani M, Lewis D, Warner A, Dar AR, Yaremko BP, Bierer J, Palma DA, Fortin D, Inculet RI, Fr  chette E, Raphael J, Gaede S, Kuruvilla S, Younus J, Vincent MD, Rodrigues GB. (2022). The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial. *Thoracic Cancer*. 13(13): 1898-1915. Published,
12. Socinski MA, Ozg  r  glu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray JE, Park K, Vincent M, Mann H, Newton M, Dennis PA, Antonia SJ. (2021). Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). *Clinical Lung Cancer*. 22(5): 549-561. Published,
13. Beatrice T B Preti, Alec Pencz, Jeffery J M Cowger, Mark D Vincent, Daniel Breadner. (2021). Skin Deep: A Fascinating Case Report of Immunotherapy-Triggered, Treatment-Refractory Autoimmune Lichen Planus and Keratoacanthoma. *Case reports in oncology*. 14(2): 1189-1193. Published,
14. Faizah Alotaibi, Mark Vincent, Wei-Ping Min, James Koropatnick. (2021). Reduced CD5 on CD8 + T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function. *Frontiers in Immunology*. 11: 584937. Published,
15. Raphael J, Batra A, Boldt G, Shah PS, Blanchette P, Rodrigues G, Vincent MD. (2020). Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. *Clinical Lung Cancer*. 21(2): 106-113. Published,
16. Raphael J, Vincent M, Boldt G, Shah PS, Rodrigues G, Blanchette P. (2019). Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis. *American Journal of Clinical Oncology*. 42(5): 440-445. Published,
17. Ko YJ, Abdelsalam M, Kavan P, Lim H, Tang PA, Vincent M, Wong R, Kish M, Gill S. (2019). What is a clinically meaningful survival benefit in refractory metastatic colorectal cancer?. *Current Oncology*. 26(2): e255-e259. Published,
18. E.Yu,A.Allan,M.Sanatani,D.Lewis,A.Warner,A.R.Dar,B.P.Yaremko,J.Bierer,L.Lowes,D.A.Palma,M.Vincent,G.Rodriguez,E.Frechette,J.Law,J.Raphael,J.Younus,R.Malthaner. (2019). Circulating Tumor Cells Predict Outcome in Trimodality Management of Advanced Non-Metastatic Esophageal Cancer: A Pre-planned Correlative Study from a Randomized Trial. *International Journal of Radiation Oncology*. 105(1): e205. Published,
19. Bami H, Goodman C, Boldt G, Vincent M. (2019). Gemcitabine-induced pseudocellulitis: a case report and review of the literature. *Current Oncology*. 26(5): e703-e706. Published,
20. Breadner D, Vincent MD, Jonker D, Cripps C, Klimo P, Biagi J, Lam W, O'Connell A, Whiston F, Stitt L, Welch S. (2018). Health related quality of life in older or frail patients with advanced colorectal cancer treated with dose reduced capecitabine. *Journal of Geriatric Oncology*. 9(6): 659-664. Published,
21. Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G. (2018). Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. *Current Oncology*. 25(5): 317-328. Published,

22. Dranitsaris G, Zhu X, Adunlin G, Vincent MD. (2018). Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. *Expert Review of Pharmacoeconomics & Outcomes Research*. 18(4): 351-357.  
Published,
23. Rodic S, Vincent MD. (2018). Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype. *International Journal of Cancer*. 142(3): 440-448.  
Published,
24. Zhang TW, Rodrigues GB, Louie AV, Palma D, Dar AR, Dingle B, Kocha W, Sanatani M, Yaremko B, Yu E, Younus J, Vincent MD. (2018). Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer. *Current Oncology*. 25(1): 22-31.  
Published,
25. Ferguson PJ, Vincent MD, Koropatnick J. (2018). Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein. *Journal of Pharmacological Experimental Theories*. 364(1): 46-54.  
Published,
26. Vincent MD, Breadner D, Soulieres D, Kerr IG, Sanatani M, Kocha W, Klimo P, MacKenzie MJ, O'Connell A, Whiston F, Malpage AS, Stitt L, Welch SA. (2017). Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer. *Future Oncology*. 13(9): 777-786.  
First Listed Author  
Published,  
Number of Contributors: 13
27. M.D. Vincent D. Breadner M.C. Cripps D.J. Jonker P. Klimo J.J. Biagi W. Lam A. O'Connell F. Whiston L. Stitt S.A. Welch. (2017). Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. *Current Oncology*. 24(4): e261-e268.  
Published,
28. Vincent MD. (2017). Cancer: Towards a general theory of the target: All successful cancer therapies, actual or potential are reducible to either (or both) of two fundamental strategies. *Bioessays*. 39(9): 1-16.  
Published,
29. Barnes TA, O'Kane GM, Vincent MD, Leighl NB. (2017). Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer. *Frontiers Oncology*. 31(7): 113.  
Published,
30. Yan M, Ho C, Winkquist E, Jonker D, Rayson D, Stitt L, Tokmakejian S, Tomiak A, Vincent MD. (2016). Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated with 5-Fluorouracil and Folinic Acid. *Clinical Colorectal Cancer*. 15(4): 369-376.  
<http://dx.doi.org/10.1016/j.clcc.2016.06.001>  
Co-Author  
Published,
31. Vincent, M. (2016). Resistance to cancer chemotherapy as an atavism?. *Bioessays*. 38: 1065.  
<http://dx.doi.org/10.1002/bies.2016.06.001>.  
First Listed Author  
Published,
32. Vincent MD. (2015). Evolutionarily conserved stress responses as potential anticancer therapeutic targets? (Comment on DOI 10.1002/bies.201300170). *Bioessays*. 36(6): 544-545.  
First Listed Author  
Published,  
Number of Contributors: 1



33. Di Cresce, Figueredo R, Rytelowski M, Maleki Vareki S, Way C, Ferguson PJ, Vincent MD, Koropatnick J. (2015). siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumour cells to gemcitabine. *Oncotarget*. 8(26): 22397-22409.  
Co-Author  
Published,
34. Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, et al. (2015). IDO Downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells. *Public Library of Science One*. 10(11): 1-22.  
Co-Author  
Published,
35. Hoover DA, Capaldi DP, Sheikh K, Palma DA et al. (2014). Functional lung avoidance for individualized radiotherapy (FLAIR): Study protocol for a randomized, double blind clinical trial. *Biomed Central Cancer*. 14(934): 1-10.  
Co-Author  
Published,
36. Lineweaver CH, Davies PC, Vincent MD. (2014). Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model. *Bioessays*. 36(9): 827-35.  
Co-Author  
Published,  
Number of Contributors: 3
37. Rytelowski M, Tong JG, Buensuceso A et al. (2014). BRCA2 inhibition enhances cisplatin-mediated alterations in tumour cell proliferation, metabolism, and metastasis. *Molecular Oncology*. 8(8): 1429-1440.  
Co-Author  
Published,
38. Korpanty GJ, Graham DM, Vincent MD, Leighl NB. (2014). Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1 and KRAS. *Frontiers in Oncology*. 4(204): 1-8.  
Co-Author  
Published,
39. Maleki Vareki S1, Rytelowski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, Min W, Zheng X, Koropatnick J. (2014). Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. *Oncotarget*. 15(5): 2778-91.  
Co-Author  
Published,  
Number of Contributors: 9
40. Vincent MD. (2014). Promising targets and current clinical trials in metastatic squamous cell lung cancer. *Frontiers in Oncology*. 4(320): 1-10.  
First Listed Author  
Published,
41. Rytelowski M, Ferguson PJ, Maleki Vareki S, Figueredo R, Vincent M, Koropatnick J. (2013). Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality". *Mol Ther Nucleic Acid*. 2: e78.  
Co-Author  
Published,  
Number of Contributors: 6

## Book Chapters

1. MarkVincent. (2016). Atavism Theory: An Introductory Discourse. Beata Ujvari, Benjamin Roche, Frederic Thomas. Ecology and Evolution of Cancer.  
Published, Academic Press, United States of America  
Description of Contribution Role: Chapter for a book

## Conference Publications

1. S.W. Strum, M. Vincent, M. Gipson, E. McArthur, D. Breadner. (2022). Serum Tumor Markers as a Surrogate for Radiographic Assessment of Non-Small Cell Lung Cancer. IASLC World Conference on Lung Cancer, Vienna, Austria,  
Conference Date: 2022/8  
Poster  
Co-Author  
Published
2. Breadner D, Liu G, Rothenstein J, Wheatley-Prince P, Bains P, Cheng S, Wang Y, Sun S, Mithoowani H, Juergens R, Cheema PK, Vincent M. (2022). Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L. International Association for the Study of Lung Cancer (IASLC), Vienna, Austria,  
Conference Date: 2022/8  
Poster  
Last Author  
Published
3. Peter J. Ferguson; Mark D. Vincent; Yousef Najajreh; Brian Shilton; Stephen Ritter; Rima Al-awar; Richard Marcellus; Mohammed Mohammed; Methvin Isaac; James Koropatnick. (2022). Synergistic antiproliferative activity of novel RAD51 inhibitor JKYN-1 and its mesylate salt with standard-of-care cancer drugs. American Association for Cancer Research (AACR) Annual Meeting, New Orleans, United States of America,  
Conference Date: 2022/6  
Poster  
Co-Author  
Published
4. Peter J. Ferguson, Hareesh Nair, Mark D. Vincent, James Koropatnick. (2022). Antiproliferative activity of EC359, an inhibitor of leukemia inhibitory factor receptor (LIF-R), singly and in combination with chemotherapy drugs against pancreatic cancer cell lines. American Association for Cancer Research (AACR) Annual Meeting, New Orleans, United States of America,  
Conference Date: 2022/6  
Poster  
Co-Author  
Published
5. Alec Pencz, Morgan Black, Scott Strum, Meghan Gipson, Mark Vincent. (2022). Examination of Febrile Neutropenia and the Utilization of G-CSF on Healthcare Systems. Canadian Association of Medical Oncologists (CAMO) Annual Meeting, Canada,  
Conference Date: 2021/4  
Abstract  
Last Author  
Accepted



6. Mark Vincent. (2017). On the nature of cancer, and why it matters. Aneuploidy and Cancer: Clinical and Experimental Aspects, ,  
Conference Date: 2017/1  
Abstract  
First Listed Author  
Published
7. Peter J Ferguson, Mateusz Rytelowski, Mark D Vincent, James Koropatnick. (2016). Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of RAD51: Targeting DNA repair to induce synthetic lethality. American Association for Cancer Research (AACR) Annual Meeting, New Orleans, United States of America,  
Conference Date: 2016/4  
Poster  
Co-Author  
Published

## Intellectual Property

### Patents

1. RAD51 binding inhibitors and methods of use thereof. United States of America. WO 2022/140860 A1. 2021/12/31.  
Patent Status: Pending
2. Methods of treating cancer and/or enhancing sensitivity to cancer treatment by increasing tumor mutation burden or tumor indels. United States of America. WO2019079891A1. 2018/10/23.  
Patent Status: Pending
3. Methods of treating cancer by inhibition of dna repair proteins using antisense based therapies. Germany. EP3393479A1. 2016/12/13.  
Patent Status: Pending
4. Antisense Oligonucleotides for Identifying Drug Targets and Enhancing Cancer Therapies. United States of America. WO2003093291A2. 2003/05/01.  
Patent Status: Pending
5. Combinations of antisense oligonucleotides directed against thymidylate synthase mrna and uses thereof. United States of America. WO2003086416A1. 2003/04/08.  
Patent Status: Pending
6. Methods of treating cancer by inhibition of DNA repair proteins using antisense based therapies. United States of America. US 20190002884 A1. 2016/12/16.  
Patent Status: Granted/Issued  
Year Issued: 2020
7. Method Of Treating Cancer By Inhibition Of DNA Repair Proteins. United States of America. US 20140113951 A1; 9,359,605. 2012/03/12.  
Patent Status: Granted/Issued  
Year Issued: 2016
8. Antisense Oligonucleotides Targeted To The Coding Region Of Thymidylate Synthase And Uses Thereof. Canada. PCT/GB98/02820 (WO99/15648). 1997/09/23.  
Patent Status: Granted/Issued  
Year Issued: 1998

## Licenses

1. Next generation of RAD51 inhibitors (2015-222)  
Granted  
Filing Date: 2015/04/10
2. IBR compounds and CML and leukemia (2006-512)  
Granted  
Filing Date: 2015/04/10
3. Discovery of compounds disrupting the interaction between BRCA2 and RAD51 proteins leads to sensitize cancer cells to chemotherapy (2005-107)  
Granted  
Filing Date: 2015/04/10